University of Maryland (UM) Ventures and Educational and Scientific LLC (ESL), announced today that the University of Maryland, Baltimore (UMB) granted ESL exclusive licensing rights to its interest in the commercial development of a molecule whose anticancer properties were jointly discovered by ESL and UMB. The molecule has consistently demonstrated its potential for the treatment of a variety of cancers, particularly lung, Non-Hodgkin’s lymphoma, pancreatic and prostate cancer.
Henry Lowe, Ph.D., D.Sc., F.R.S.H., an Adjunct Professor of Medicine at the University of Maryland School of Medicine (UM SOM) is the Founder of ESL. Dr. Lowe collaborated with Dr. Joseph Bryant, DVM, Associate Professor of Pathology and Director, Animal Models Division, at the UM SOM Institute of Human Virology (IHV) in the realization of this discovery.